Ferrous Bisglycinate for Health & Longevity

Created on 11/07/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Ferrous bisglycinate, a dietary supplement form of iron bound to the amino acid glycine, is used to treat low iron. In people truly low in iron, strong evidence shows it corrects deficiency and anemia, with fewer digestive side effects at the lower doses it allows. With adequate iron, no evidence shows benefit for health or lifespan, and unneeded use can lead to iron accumulation the body cannot remove. (Full Review)

Protocol

Repletion dose
60 mg elemental iron daily
For 56 days in deficiency; single daily dose, alternate days nearly matched daily dosing
Prevention dose
25 mg daily
Appeared adequate in pregnancy; 18 mg was inferior to 60 mg ferrous sulfate
Time of day
Morning, empty stomach
30–60 minutes before breakfast, away from coffee, tea and calcium
Time to effect
Hemoglobin
4–8 weeks
About 1.2 g/dL rise by week 4 and 2.6 g/dL by week 8 on a 60 mg multi-ingredient tablet
Ferritin stores
Slower than hemoglobin
Protocols continue about 3 months after hemoglobin normalizes to refill stores
Fatigue
12 weeks
Improvement measured in fatigued iron-deficient women

Benefits

Contraindications
  • Hereditary hemochromatosis or iron overload (transferrin saturation above 45% with ferritin above 200 µg/L in premenopausal women, or above 50% with ferritin above 300 µg/L in men and postmenopausal women)
  • Anemia not caused by iron deficiency (thalassemia trait, anemia of chronic inflammation) with normal or high ferritin
  • Peptic ulcer or inflammatory bowel disease (regional enteritis, ulcerative colitis)
  • Households with children under six, unless products are stored out of reach
Key Interactions
  • Levothyroxine
  • Levodopa/carbidopa (Sinemet)
  • Fluoroquinolone antibiotics (ciprofloxacin, levofloxacin)
  • Tetracycline antibiotics (doxycycline, tetracycline)
  • Acid suppressants, prescription and over-the-counter (omeprazole, pantoprazole; famotidine)
  • Calcium supplements, calcium antacids and dairy (calcium carbonate, milk)
  • Tea and espresso coffee
  • Green tea extract
  • Other iron supplements and iron-containing multivitamins (ferrous sulfate, ferrous fumarate)
  • Intravenous iron
Theoretical (inferred from mechanism)
  • Testosterone therapy (testosterone cypionate, enanthate)
  • Iron-binding polyphenol supplements (curcumin, quercetin)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Gastrointestinal adverse events; iron accumulation in iron-replete users and hemochromatosis carriers; delayed diagnosis of the cause of iron deficiency; accidental iron poisoning in young children
  • Speculative: Gut microbiome shift toward potentially pathogenic bacteria

Monitoring

Marker Target Why
Ferritin Above 45 µg/L; below 200 µg/L (premenopausal women) or 300 µg/L (men, postmenopausal women) Expected to change; safety check for overload
Transferrin saturation Below 45% (premenopausal women) or 50% (men, postmenopausal women) Safety check for overload
Hemoglobin 13.5–17.5 g/dL (men); 12.0–15.5 g/dL (women) Expected to change; confirms response
CRP Not specified in the ER Inflammation falsely raises ferritin
MCV Not specified in the ER Normalizes as deficiency resolves
TSH (levothyroxine users only) 0.4–4.0 mU/L Signals the iron–levothyroxine interaction

Cadence: Baseline before starting; repeat at 4 weeks, then at 8–12 weeks, then every 6–12 months for maintenance users; TSH 6–8 weeks after starting iron

Qualitative Assessment

  • Energy and fatigue: daytime tiredness and mental stamina
  • Exercise tolerance: breathlessness, heart rate and perceived effort at familiar workloads
  • Restless legs: evening leg discomfort and urge to move
  • Gastrointestinal tolerance: nausea, constipation, abdominal pain; dark stools are expected and harmless
  • Other deficiency signs: cold intolerance, brittle nails, hair shedding and cravings for ice